Physician profile
Brian D Baxter
NPI 1831126697
$1,716.89
in general payments reported to CMS, 2019-2025
19 companies · $82.37 in 2025
The $82.37 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.50 · 2020: $53.21 · 2021: $328 · 2022: $196 · 2023: $653 · 2024: $380 · 2025: $82.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $418.47 | 2019-2024 | Clareon, Rocklatan, Simbrinza |
| Abbvie INC. | $253.04 | 2022-2024 | Lumigan, Alphagan P, Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $206.47 | 2021 | |
| Bausch & Lomb Americas INC. | $193.88 | 2022-2024 | Miebo, Vyzulta, Lotemax Sm |
| Glaukos Corporation | $150.76 | 2023 | Kxl System (Not Refurbished) |
| Allergan, INC. | $90.18 | 2020-2021 | |
| Akorn Operating Company LLC | $52.31 | 2021 | |
| Sun Pharmaceutical Industries INC. | $43.18 | 2023-2024 | Cequa |
| Rxsight INC | $42.41 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Novartis Pharmaceuticals Corporation | $40.08 | 2020-2022 | |
| Oyster Point Pharma, INC. | $37.60 | 2022-2023 | Tyrvaya |
| Alexion Pharmaceuticals, INC. | $33.90 | 2023 | Ultomiris |
| Tarsus Pharmaceuticals, INC. | $30.87 | 2025 | Xdemvy |
| Dompe US, INC. | $29.60 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $28.43 | 2024 | Acthar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.90 | 2025 | Tepezza |
| Thea Pharma INC. | $16.44 | 2023 | Iyuzeh |
| Horizon Therapeutics Plc | $15.68 | 2022 | |
| Shire North American Group INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.